{"schema_version":"secwatch.filing_event.v1","accession":"0001822479-24-000017","form_type":"8-K/A","ticker":"SHC","cik":"0001822479","company_name":"Sotera Health Co","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.396894+00:00","generated_at":"2026-06-03T00:49:24.833275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sotera Health Q1 revenue up 12.5% to $248M; net income $6M; reaffirms 2024 outlook","bullets":["Q1 net revenues $248M (+12.5% YoY); net income $6M ($0.02 diluted EPS) vs $3M ($0.01) in Q1 2023.","Adjusted EBITDA $112M (+13.7% YoY); Adjusted EPS $0.13 flat YoY.","Sterigenics segment net revenues $166M (+4.1%), segment income $86M (+3.6%).","Co reaffirms 2024 outlook; cites EPA finalizing updated NESHAP for ethylene oxide as manageable.","8-K/A filed to correct typo in prior exhibit; no impact on reported income metrics."],"urls":{"canonical":"https://secwatch.observer/filing/0001822479-24-000017","json":"https://secwatch.observer/filing/0001822479-24-000017.json","markdown":"https://secwatch.observer/filing/0001822479-24-000017.md","text":"https://secwatch.observer/filing/0001822479-24-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822479/000182247924000017/0001822479-24-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822479/000182247924000017/shc-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:49:24.833275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f409d30a20cdcab32824d88e6ad2facf8ff55270","claim":"Sotera Health Co reported the three months ended March 31, 2024 results: revenue $248 million, net income $6 million, EPS $0.02 per diluted share. Guidance reaffirmed.","evidence_excerpt":"First-quarter 2024 net revenues increased 12.5% to $248 million, compared to $221 million in the first-quarter 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822479/000182247924000017/0001822479-24-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$248 million"},{"label":"Net income","value":"$6 million"},{"label":"EPS","value":"$0.02 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}